SPYRE THERAPEUTICS, INC. Operating Cash Flow
SPYRE THERAPEUTICS, INC. (SYRE) reported Operating Cash Flow of -$127.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$69.88M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$57.37M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$44.58M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$37.12M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$169.25M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$157.41M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$99.91M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$80.14M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$69.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$127.25M 10-Q · filed 2026-08-04 | -$171.83M derived: sum of 3 quarters · filed 2026-08-04 | -$208.94M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$57.37M 10-Q · filed 2026-05-05 | -$101.95M derived: sum of 2 quarters · filed 2026-05-05 | -$139.07M derived: sum of 3 quarters · filed 2026-05-05 | -$185.63M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$44.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$81.69M derived: sum of 2 quarters · filed 2026-02-19 | -$128.26M derived: sum of 3 quarters · filed 2026-08-04 | -$169.25M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$37.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$83.68M derived: sum of 2 quarters · filed 2026-08-04 | -$124.67M 10-Q · filed 2025-11-04 | -$161.87M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$46.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$87.56M 10-Q · filed 2026-08-04 | -$124.76M derived: sum of 3 quarters · filed 2026-08-04 | -$154.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$40.99M 10-Q · filed 2026-05-05 | -$78.19M derived: sum of 2 quarters · filed 2026-05-05 | -$107.61M derived: sum of 3 quarters · filed 2026-05-05 | -$169.86M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$37.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$66.62M derived: sum of 2 quarters · filed 2026-02-19 | -$128.87M derived: sum of 3 quarters · filed 2026-02-19 | -$157.41M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$29.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$91.67M derived: sum of 2 quarters · filed 2025-11-04 | -$120.21M 10-Q · filed 2025-11-04 | -$151.25M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$62.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$90.79M 10-Q · filed 2025-08-05 | -$121.83M derived: sum of 3 quarters · filed 2026-02-19 | -$156.42M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$28.54M 10-Q · filed 2025-05-08 | -$59.58M derived: sum of 2 quarters · filed 2026-02-19 | -$94.17M derived: sum of 3 quarters · filed 2026-02-19 | -$110.82M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$31.04M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | -$65.63M derived: sum of 2 quarters · filed 2026-02-19 | -$82.28M derived: sum of 3 quarters · filed 2026-02-19 | -$99.91M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$34.60M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$51.24M derived: sum of 2 quarters · filed 2024-11-18 | -$68.87M 10-Q/A · filed 2024-11-18 | -$87.01M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$16.64M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | -$34.28M 10-Q/A · filed 2024-11-18 | -$52.42M derived: sum of 3 quarters · filed 2025-02-27 | -$67.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$17.63M 10-Q/A · filed 2024-11-18 | -$35.77M derived: sum of 2 quarters · filed 2025-02-27 | -$50.84M derived: sum of 3 quarters · filed 2025-02-27 | -$71.52M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$18.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$33.21M derived: sum of 2 quarters · filed 2025-02-27 | -$53.88M derived: sum of 3 quarters · filed 2025-02-27 | -$80.14M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$15.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$35.74M derived: sum of 2 quarters · filed 2023-11-09 | -$62.00M 10-Q · filed 2023-11-09 | -$81.27M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | -$20.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$46.94M 10-Q · filed 2023-08-11 | -$66.20M derived: sum of 3 quarters · filed 2024-11-18 | -$83.20M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | -$26.26M 10-Q · filed 2023-05-11 | -$45.53M derived: sum of 2 quarters · filed 2024-11-18 | -$62.53M derived: sum of 3 quarters · filed 2024-11-18 | -$60.45M derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | -$19.27M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | -$36.27M derived: sum of 2 quarters · filed 2024-11-18 | -$34.19M derived: sum of 3 quarters · filed 2024-11-18 | -$53.72M 10-K/A · filed 2024-11-18 |
| 2021-09-30 | -$17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$14.92M derived: sum of 2 quarters · filed 2022-11-03 | -$34.45M 10-Q · filed 2022-11-03 | -$51.58M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$17.45M 10-Q · filed 2022-08-04 | -$34.58M derived: sum of 3 quarters · filed 2023-03-02 | -$52.12M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | -$19.53M 10-Q · filed 2022-05-05 | -$36.66M derived: sum of 2 quarters · filed 2023-03-02 | -$54.20M derived: sum of 3 quarters · filed 2023-03-02 | -$73.61M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | -$17.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$34.67M derived: sum of 2 quarters · filed 2023-03-02 | -$54.08M derived: sum of 3 quarters · filed 2023-03-02 | -$75.78M 10-K · filed 2023-03-02 |
| 2020-09-30 | -$17.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$36.95M derived: sum of 2 quarters · filed 2021-11-04 | -$58.64M 10-Q · filed 2021-11-04 | -$74.94M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | -$19.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$41.11M 10-Q · filed 2021-08-05 | -$57.40M derived: sum of 3 quarters · filed 2022-03-08 | -$74.61M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | -$21.69M 10-Q · filed 2021-05-10 | -$37.99M derived: sum of 2 quarters · filed 2022-03-08 | -$55.20M derived: sum of 3 quarters · filed 2022-03-08 | -$71.58M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | -$16.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$33.50M derived: sum of 2 quarters · filed 2022-03-08 | -$49.88M derived: sum of 3 quarters · filed 2022-03-08 | -$65.69M 10-K · filed 2022-03-08 |
| 2019-09-30 | -$17.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$33.59M derived: sum of 2 quarters · filed 2020-11-05 | -$49.40M 10-Q · filed 2020-11-05 | -$56.60M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | -$16.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$32.19M 10-Q · filed 2020-08-10 | -$39.39M derived: sum of 3 quarters · filed 2021-03-18 | -$47.89M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | -$15.81M 10-Q · filed 2020-05-07 | -$23.01M derived: sum of 2 quarters · filed 2021-03-18 | -$31.51M derived: sum of 3 quarters · filed 2021-03-18 | -$40.55M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | -$7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$15.70M derived: sum of 2 quarters · filed 2021-03-18 | -$24.75M derived: sum of 3 quarters · filed 2021-03-18 | -$32.19M 10-K · filed 2021-03-18 |
| 2018-09-30 | -$8.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$17.55M derived: sum of 2 quarters · filed 2019-11-06 | -$24.99M 10-Q · filed 2019-11-06 | -$30.87M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | -$9.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$16.49M 10-Q · filed 2019-08-06 | -$22.36M derived: sum of 3 quarters · filed 2020-02-24 | |
| 2018-03-31 | -$7.45M 10-Q · filed 2019-05-07 | -$13.32M derived: sum of 2 quarters · filed 2020-02-24 | ||
| 2017-12-31 | -$5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | -$24.61M 10-K · filed 2020-02-24 | ||
| 2017-09-30 | -$18.74M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | -$18.84M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |